evenfolio

Healthcare · NSE: NEPHROPLUS

Nephrocare Health Services

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
642.00−1.39%

Q2 FY27 earnings call · Guided by management

Call held 4 Nov 2026 · Read the filing on NSEFiling

15–20​%Revenue growth · three to four yearsGoenka · p. 6
40–50​clinicsClinic additions per year · India and Philippines · every yearManagement · Q&A · p. 11
40–50​clinicsClinic additions per year · India · per yearVuppala · Q&A · p. 14
₹102​CrCapital deployed · H1 FY27Goenka · p. 6
M.Cap
₹6,456Cr
P/E
50.4×
1Y return
—
From 52W high
−17.9%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Year agoYoYQ1 FY27QoQ
Revenue303——282+7.7%
EBITDA67——64+5.1%
EBITDA margin22.1%——22.7%-55 bps
PBTProfit before tax44——45-0.6%
Net profit34——32+4.9%
EPS (₹)3.25——3.11+4.5%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · long term15-20%keptMedium-term revenue growth guidance of 15% to 20% over three to four years reiterated
New stores · India and Philippines · FY2740-50 clinicsAim to add about 40-50 clinics a year in India and 10-15 in the Philippines; on track this year
New stores · India · FY2740-50 clinicsIndia clinic addition guidance of 40-50 kept; could be slightly higher than 50

Medium-term guidance kept unchanged in closing remarks

Vikram Vuppala · Chairman and Managing Director · p. 23
“We entered Kazakhstan, our sixth country, last quarter, and we also continue to keep our medium-term guidance unchanged.”

More figures from the call

India · Capacity
75​%Capacity utilisation
“Our capacity utilization at the India network level is 75% approximately.”
Rohit Singh · Group Chief Executive Officer · Q&Ap. 12
Company · Capacity
74​%Capacity utilisation
“Our overall capacity utilization currently is 74%. As Rohit mentioned, this is a decent utilization.”
Prashant Goenka · Group Chief Financial Officer · Q&Ap. 15
Company · Capacity
90​%Maximum theoretical utilisation
“There is obviously little room to grow, but dialysis business does not operate at 100% utilization. Typically, it will operate the max out or the maximum theoretical max is around 90%.”
Rohit Singh · Group Chief Executive Officer · Q&Ap. 12
Saudi Arabia · Segments
4–5​monthsTender evaluation period · 4 months to 5 months
“Then it will go through an evaluation stage for another 4 months to 5 months.”
Rohit Singh · Group Chief Executive Officer · Q&Ap. 22
Kazakhstan · Segments
1​yearTime to steady-state margins · about a year
“Our focus is now to integrate the Almaty clinics and grow from there, including through acquisitions that meet our thresholds. We expect about a year to reach a steady state margins.”
Rohit Singh · Group Chief Executive Officerp. 4
Company · Segments
12–18​monthsNew geography frequency · every 12 to 18 months
“Opening new geography is a key pillar for growth, and as we said, this will happen every 12 to 18 months.”
Vikram Vuppala · Chairman and Managing Directorp. 3

In short

  1. 01Medium-term guidance of 15% to 20% revenue growth over three to four years was reiterated; no annual guidance is given.
  2. 02Q2 revenue grew 23.5% to Rs 303 crore; H1 adjusted EBITDA was Rs 134 crore at a 23% margin.
  3. 03H1 EBITDA margin of 23.0% was about 80 bps below FY26's 23.8%, put down to higher other expenses.
  4. 04FY27 capital deployment is expected to exceed FY26's Rs 165 crore; Rs 102 crore deployed in H1.
  5. 05Company aims to add 40-50 clinics a year in India and 10-15 in the Philippines.
  6. 06Entered Kazakhstan with two clinics in Almaty; about a year expected to reach steady-state margins.
  7. 07Technically qualified for Saudi MoH dialysis tender; bids due February 2027, no assurance of winning.
  8. 08Net cash: about Rs 507 crore cash and investments against Rs 80 crore borrowings at 30 September.

Capex

FY27 capital deployment expected to exceed FY26's Rs 165 crore as newest geography is built out

Prashant Goenka · Group Chief Financial Officer · p. 6
“We expect FY27 capital deployment to exceed FY26 INR165 crores as we build out our newest geography.”

No precise FY27 capex figure; will be more than Rs 165 crore, Rs 102 crore spent

Prashant Goenka · Group Chief Financial Officer · Q&A · p. 21
“While I cannot give you a precise number, but I think that will give you an idea that it will be more than INR165 crores, and we have already spent INR102 crores.”

Saudi Arabia: Additional Saudi capex if tender is won would come in the next financial year

Rohit Singh · Group Chief Executive Officer · Q&A · p. 22
“Yes, absolutely. That will be in the next financial year. Next financial year. As I said, the tender submission is only in February 2027, and evaluation will take another 5 months, 6 months.”

Saudi Arabia: Saudi Arabia considerably more capex-heavy than India

Rohit Singh · Group Chief Executive Officer · Q&A · p. 16
“Deepika, we do not get into specifics of capex per country, but it is obvious that the Saudi Arabia is considerably more capex-heavy as compared to India or any other business.”

Capacity

Utilisation improvement from here expected to be marginal

Prashant Goenka · Group Chief Financial Officer · Q&A · p. 15
“We believe we can improve it, and we have improved it in the last few quarters, but it will be marginal.”

Segments

Saudi Arabia: Saudi tender bids due February 2027; Saudi stays in investment phase until awards

Rohit Singh · Group Chief Executive Officer · p. 5
“Bids are due in February 2027. Until the awards are known, Saudi remains an investment phase for us.”

International: International mix about 47% of revenue, up from 42% in FY26, driving revenue per treatment

Prashant Goenka · Group Chief Financial Officer · p. 5
“Revenue per treatment rose 9.7% to INR2,785 for the first half year, driven mainly by international mix, which reached about 47% of revenue, up from 42% in FY26.”

Philippines: Philippines crossed 55 clinics, adding 11 this year including 10 acquisitions in H1

Rohit Singh · Group Chief Executive Officer · p. 4
“Philippines, we crossed 55 clinics, adding 11 this year, including 10 acquisitions in the first half.”

Philippines: Philippines greenfield strategy to be explored in short to medium term

Rohit Singh · Group Chief Executive Officer · Q&A · p. 21
“I think we will explore the greenfield strategy I mentioned in my remarks also, that we will be exploring the greenfield strategy in short to medium term. So, I think we are almost there, and we will execute that.”

India: India PPP: Bihar scaling, Tamil Nadu rolling out, six-clinic contract won in Haryana

6​clinics
Rohit Singh · Group Chief Executive Officer · p. 4
“In public-private partnership, Bihar continues to scale, and we are rolling out our Tamil Nadu contract as well. We also secured a contract for six clinics in Haryana.”

Demand

Saudi Arabia: Saudi MoH tender covers about 11,720 patients across four clusters

Rohit Singh · Group Chief Executive Officer · p. 5
“The Ministry of Health tender has been issued, covering about 11,720 patients across four clusters.”

Kazakhstan: Kazakhstan has about 12,000 dialysis patients in 150 clinics; prices about $75-$80 per treatment

Rohit Singh · Group Chief Executive Officer · p. 4
“The country has around 12,000 dialysis patients across 150 clinics, with universal coverage and prices of roughly $75 to $80 per treatment.”

Kazakhstan: Two large players control about 60%-65% of Kazakhstan market

Rohit Singh · Group Chief Executive Officer · Q&A · p. 17
“The largest is a local player there, which is already in operation for the last 15 years. Between both of them, I think they control close to 60%-65% of the market.”

Philippines: Philippines has about 900 clinics, 500-plus with small owners, giving roll-up visibility

Rohit Singh · Group Chief Executive Officer · p. 4
“The market has around 900 clinics, with a long tail of 500-plus clinics owned by individuals running one or two clinics. That fragmentation gives us multi-year visibility for roll-ups, complemented by a greenfield strategy.”

Saudi Arabia: Saudi tender envisages 10% to 15% of volume moving to home care

Rohit Singh · Group Chief Executive Officer · Q&A · p. 10
“And the Saudi new tender that has also come in talks about having 10% to 15% of the volume move towards home care.”

Margins and costs

H1 adjusted EBITDA Rs 134 crore, up 15.3%, at 23% margin

Prashant Goenka · Group Chief Financial Officer · p. 5
“Adjusted EBITDA for the first half year was INR134 crores, up 15.3% at 23% margin.”

Q2 adjusted EBITDA Rs 68.9 crore, up 3.3% year-on-year, at 22.7% margin

Prashant Goenka · Group Chief Financial Officer · p. 5
“Q2 adjusted EBITDA was INR68.9 crores, up 3.3% year-on-year, and 5.8% over Q1, at a 22.7% margin.”

EBITDA margin 23.0% in H1 FY27 vs 23.8% in FY26, about 80 bps lower

Prashant Goenka · Group Chief Financial Officer · p. 5
“On that basis, EBITDA margin was 23.8% in FY26 against 23.0% in H1 FY27, a reduction of about 80 basis point.”

Other expenses rose from 18.2% of revenue in FY26 to 20% in H1

Prashant Goenka · Group Chief Financial Officer · p. 5
“Some of this compression is due to higher other expenses, which rose from 18.2% in FY26 to 20% in the first half.”

COGS fell about 95 bps to 22% of revenue; professional and hospital fees fell 83 bps to 18.4%

Prashant Goenka · Group Chief Financial Officer · p. 6
“Materials or COGS fell about 95 basis point to 22% of revenue. Professional and hospital fees fell about 83 basis point to 18.4% of revenue.”

Debt and working capital

Finance costs fell from Rs 51 crore to Rs 5.3 crore after repaying borrowings from IPO proceeds

Prashant Goenka · Group Chief Financial Officer · p. 6
“Finance costs fell from INR51 crores to INR5.3 crores after we repaid borrowings from IPO proceeds, and other income rose to INR15.1 crores.”

Net cash: about Rs 507 crore cash and investments vs Rs 80 crore borrowings at 30 September

Prashant Goenka · Group Chief Financial Officer · p. 6
“We remain comfortably net cash, with cash deposit and investment of about INR507 crores against the borrowing of INR80 crores as of 30th September.”

H1 operating cash flow Rs 89 crore, about 67% of adjusted EBITDA; Rs 52.4 crore in Q2

Prashant Goenka · Group Chief Financial Officer · p. 6
“Operating cash flow for the half year was INR89 crores, about 67% of our adjusted EBITDA, of which INR52.4 crores came in Q2.”

Acquisitions and new business

Saudi Arabia: Saudi MoH tender: one of 12 providers qualified, only one from Asia, for four regions

Vikram Vuppala · Chairman and Managing Director · p. 3
“We are one of the 12 providers and the only one from Asia who qualified to bid for four regions of this tender.”

Kazakhstan: Entered Kazakhstan this quarter by acquiring two clinics in Almaty

2​clinics
Rohit Singh · Group Chief Executive Officer · p. 4
“Kazakhstan is our newest market, entered this quarter through the acquisition of two clinics in Almaty.”

Saudi Arabia: Company holds 51% of Saudi JV, shown as single line below EBITDA

Prashant Goenka · Group Chief Financial Officer · Q&A · p. 22
“Nilanjan, just to add to what Rohit said, we have 51% share in the JV, and whatever contribution comes from this geography does not go through a line-by-line consolidation.”

GFR CKD care platform in pilot; select patients onboarded for trials

Rohit Singh · Group Chief Executive Officer · p. 5
“GFR, our CKD care platform, is in the pilot stage. We have begun on boarding select patients for trials.”

Rs 507 crore cash; evaluating growth opportunities in India and abroad

Management · Q&A · p. 15
“We are currently sitting on INR507 crores of cash. We are evaluating, and we will continue to evaluate growth opportunities both in India and international.”

One-offs

Saudi Arabia: Saudi JV loss share of Rs 7.5 crore in H1, shown below EBITDA, added back in adjusted PAT

Prashant Goenka · Group Chief Financial Officer · p. 6
“Our share of Saudi JV loss was INR7.5 crores for the first half year, shown below EBITDA and added back in the adjusted PAT.”

Risks

Saudi Arabia: Management says it cannot assure it will win any region of the Saudi tender

Vikram Vuppala · Chairman and Managing Director · p. 3
“While we are doing everything we can to improve the chances of winning this tender, of winning a region, by no means we can assure you that we will be one of the winners in this process.”

Philippines: Philippines competition growing; company says it is second-largest network there

Rohit Singh · Group Chief Executive Officer · Q&A · p. 9
“So I think we will continue our momentum there in Philippines, but obviously, there is competition that is growing up.”

Pharmacy products under 1% of revenue; no major impact seen from margin caps

Vikram Vuppala · Chairman and Managing Director · p. 4
“We just want to let you know that pharmacy products account for less than 1% of our overall revenue, and we do not make much margins on that small base. Hence, we do not expect to see any major impact even if these guidelines make their way from cancer care products to dialysis-related products.”

Trade margin cap seen as not relevant to dialysis industry

Vikram Vuppala · Chairman and Managing Director · Q&A · p. 19
“The delta between the acquisition cost and the MRP is negligible, or very, very reasonable. I do not think that's relevant to dialysis industry at all.”

International: Access to trained renal nurses named as a constraint on international expansion

Rohit Singh · Group Chief Executive Officer · p. 5
“Access to trained renal nurse is a real constraint on international expansion, and we intend to solve it structurally rather than market-by-market.”

Other

Q2 revenue up 23.5% to Rs 303 crore; H1 revenue Rs 585 crore, up 24%

Rohit Singh · Group Chief Executive Officer · p. 4
“The quarter, Q2 revenue grew 23.5% year on year to INR303 crores, taking H1 revenue to INR585 crores, up 24%.”

Adjusted PAT Rs 76.1 crore, up 34.7%, margin up 107 bps to 13%

Prashant Goenka · Group Chief Financial Officer · p. 6
“Now coming to profit, adjusted PAT was INR76.1 crores, up 34.7%, with margin up 107 basis points to 13%.”

Quarterly margins not comparable with last year due to quarterly audits; Q2 FY26 margin was 27.1%

Prashant Goenka · Group Chief Financial Officer · p. 5
“Our quarterly margins this year are therefore not directly comparable with the same quarter last year. Q2 FY26, 27.1% margin is a case in point.”

Network at 570 clinics in six countries: 500 in India, 70 international

Rohit Singh · Group Chief Executive Officer · p. 4
“Our network now stands at 570 clinics across six countries, with 500 in India, 70 international.”

Guests at 38,814, up 10%; treatments up 12%; revenue per treatment up 10% to Rs 2,785

Rohit Singh · Group Chief Executive Officer · p. 4
“We ended September with 38,814 guests, up 10% year-on-year. Treatments grew faster, up 12% in the quarter, while revenue per treatment improved by 10% to INR2,785.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools